Combination strategies—for example, dual TIGIT/PD-1 blockade or STING agonists plus PD-1 inhibitors—have generated higher response rates in select PD-L1–high and MSI-high cohorts but also highlight tumor-intrinsic resistance mechanisms in “cold” microsatellite-stable colorectal cancers. Here, STING1 is linked to neoplasm.